Avatrombopag (Everest)

✅ Product Overview

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate bone marrow platelet production and help reduce the risk of bleeding caused by thrombocytopenia.

By activating the TPO receptor pathway involved in platelet production, Avatrombopag supports the body’s natural generation of platelets rather than directly replacing blood or platelets through transfusion. For many chronic patients, this offers a safer and more sustainable long-term treatment approach.

📌 Approved Indications

Avatrombopag has been approved in multiple countries for the following patient groups:

Chronic Liver Disease (CLD)

Used to temporarily increase platelet counts before scheduled invasive procedures such as biopsies or endoscopic procedures, helping reduce bleeding risk during treatment.

Chronic Immune Thrombocytopenia (ITP)

Indicated for adult patients with chronic ITP who have shown insufficient response or intolerance to corticosteroids, immunoglobulins, or splenectomy, and may be used as long-term maintenance therapy.

💊 Dosage and Administration

(For reference only — follow physician guidance)

▶ For CLD Patients Prior to Procedures

Dosage is determined according to baseline platelet levels:

Procedures are generally scheduled 10–13 days after completion of treatment.

▶ For Chronic ITP Treatment

• Typical starting dose: 20 mg once daily (1 tablet)
• Dose adjustments may range between 5 mg and 40 mg depending on platelet response
• Long-term treatment may be used to maintain platelet counts above a safe threshold (commonly >50×10⁹/L)

💡 Frequently Asked Questions

❓ How quickly does Avatrombopag work?

• CLD patients: Platelet counts often increase within 3–5 days
• ITP patients: Many patients respond within 1–2 weeks, although individual response times may vary

❓ Can it be used long term?

For chronic ITP, Avatrombopag is approved for long-term maintenance therapy.

Compared with injectable TPO receptor agonists such as eltrombopag or romiplostim, Avatrombopag offers the convenience of oral administration and is generally well tolerated.

❓ Does it increase blood clot risk?

Some patients may experience increased thrombotic risk if platelet counts rise rapidly, especially those with liver disease or cardiovascular history.

Regular platelet monitoring is important, and dose adjustments may be required when necessary.

⚠️ Important Precautions

• Avoid combining with other platelet-boosting medications unless directed by a physician
• Patients with liver disease may require careful dose adjustment and monitoring
• Pregnant or breastfeeding patients should consult a healthcare provider before use
• Regular blood tests are recommended to monitor platelet counts and liver function during treatment

📦 Storage & Administration Tips

• Store at room temperature away from moisture and direct sunlight
• May be taken with or without food, preferably at the same time each day
• If a dose is missed, take it as soon as possible; if more than 24 hours have passed, skip the missed dose and continue the regular schedule
• Do not double the dose to make up for a missed dose

If you are managing chronic ITP or thrombocytopenia related to liver disease, Avatrombopag may provide an internationally recognized oral treatment option with proven efficacy and convenience. Professional consultation and individualized treatment guidance are recommended before use.